<DOC>
	<DOC>NCT01597063</DOC>
	<brief_summary>Pregnant women with low risk indicators for fetal chromosomal aneuploidy will be enrolled. Study blood will be collected in the first or second trimester at a scheduled prenatal screening visit, processed to plasma, and stored frozen until analysis. Each pregnancy will be followed until delivery and the birth outcome recorded.</brief_summary>
	<brief_title>Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies</brief_title>
	<detailed_description />
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Aneuploidy</mesh_term>
	<mesh_term>Trisomy</mesh_term>
	<criteria>Pregnancy is 1022 weeks gestation Between 1834 years of age inclusive at estimated date of delivery No prenatal screening indicators for high risk including serum biochemical and ultrasound screening No personal or family history of Down syndrome Willing to provide written informed consent Willing to provide a whole blood sample Willing to provide access to medical records supporting fetal outcome Fetal demise at the time of the blood draw Previous specimen donation under this protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>